221
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:November 30, 2022Recruiting
Refractory Multiple Myeloma: 1467 Clinical Trials, Page 23 of 147
Hide Studies Not Open or Pending
222
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 19, 2014Terminated
223
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 16, 2017Terminated
224
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:September 4, 2015No longer available
225
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:September 20, 2017Completed
226
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:May 15, 2019Unknown status
227
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:July 5, 2019Unknown status
228
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:June 8, 2006Completed
229
Study of BCMA CAR-T in Multiple Myeloma
Condition(s):Relapsed and Refractory Multiple MyelomaLast Updated:June 18, 2018Unknown status
230
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
Condition(s):Multiple Myeloma; Relapse Multiple Myeloma; Refractory Multiple MyelomaLast Updated:December 9, 2021Recruiting